Abstract
J-147, a synthetic derivative of curcumin, has emerged as a promising therapeutic candidate for neurodegenerative diseases, particularly Alzheimer’s disease (AD). Unlike traditional approaches that target amyloid-beta accumulation, J-147 operates through a multi-targeted mechanism involving mitochondrial modulation, enhancement of brain-derived neurotrophic factor (BDNF) signaling, and cognitive function improvement. This article delves into the molecular mechanisms of J-147, emphasizing its interaction with mitochondrial ATP synthase, activation of the AMPK/mTOR pathway, upregulation of BDNF, and subsequent cognitive benefits.(PubMed Central, PubMed Central)
Introduction
Alzheimer’s disease (AD) is characterized by progressive cognitive decline, synaptic dysfunction, and neuronal loss. Traditional therapeutic strategies have largely focused on amyloid-beta and tau pathologies, yielding limited clinical success. Emerging evidence suggests that mitochondrial dysfunction and impaired neurotrophic support play pivotal roles in AD pathogenesis. J-147, developed through phenotypic screening for neuroprotective compounds, has demonstrated efficacy in preclinical models by targeting these underlying mechanisms.(PubMed Central, PubMed)
Mitochondrial Modulation by J-147
Targeting ATP Synthase
Mitochondrial ATP synthase (complex V) is essential for cellular energy production. J-147 has been identified to bind specifically to the ฮฑ-F1 subunit (ATP5A) of ATP synthase, leading to partial inhibition of its activity . This interaction results in a mild decrease in ATP production, which paradoxically activates adaptive cellular stress responses.(PubMed, PubMed Central)
Activation of AMPK/mTOR Pathway
The partial inhibition of ATP synthase by J-147 leads to an increase in intracellular calcium levels, activating calcium/calmodulin-dependent protein kinase kinase ฮฒ (CAMKK2). This activation subsequently stimulates AMP-activated protein kinase (AMPK), a key energy sensor that regulates cellular metabolism. Activated AMPK inhibits the mechanistic target of rapamycin (mTOR) pathway, promoting autophagy and enhancing cellular stress resistance .(PubMed, PubMed Central)
Mitohormesis and Longevity
The concept of mitohormesis describes how mild mitochondrial stress can induce adaptive responses that enhance cellular resilience and longevity. J-147-induced partial inhibition of ATP synthase exemplifies this, as it triggers protective pathways without causing detrimental energy deficits. In Drosophila models, J-147 administration extended lifespan and improved mitochondrial function .(PubMed Central, PubMed Central)
Enhancement of BDNF Signaling
Brain-derived neurotrophic factor (BDNF) is crucial for neuronal survival, synaptic plasticity, and cognitive function. J-147 has been shown to increase BDNF levels in the hippocampus, leading to enhanced synaptic protein expression and long-term potentiation (LTP) . These effects contribute to improved learning and memory in animal models.(PubMed Central)
Moreover, BDNF plays a role in mitochondrial function by promoting energy production and supporting synaptic activity. Thus, J-147’s ability to upregulate BDNF not only enhances cognitive function but also supports mitochondrial health .
Cognitive Function Improvement
J-147’s multifaceted mechanisms culminate in significant cognitive benefits. In aged AD mouse models, J-147 administration reversed cognitive deficits, improved spatial memory, and reduced synaptic loss . These improvements are attributed to the compound’s combined effects on mitochondrial function, BDNF signaling, and synaptic integrity.(PubMed Central)
Additionally, J-147 has demonstrated efficacy in enhancing cognitive performance in healthy aged mice, suggesting potential applications beyond neurodegenerative conditions .
Conclusion
J-147 represents a promising therapeutic agent that addresses multiple facets of neurodegeneration. By modulating mitochondrial function, enhancing BDNF signaling, and improving cognitive performance, J-147 offers a comprehensive approach to combating age-related cognitive decline and neurodegenerative diseases. Further clinical investigations are warranted to translate these preclinical findings into effective treatments for human patients.(PubMed Central)
References
- Currais A, et al. The mitochondrial ATP synthase is a shared drug target for aging and dementia. Aging Cell. 2019;18(5).(PubMed Central)
- Chin D, et al. Deciphering the ‘Elixir of Life’: Dynamic Perspectives into the Allosteric Modulation of Mitochondrial ATP Synthase by J147. ChemMedChem. 2019;14(10):905-915.(PubMed)
- Swerdlow RH. Targeting Mitochondria in Alzheimer disease: Rationale and Perspectives. Curr Alzheimer Res. 2019;16(4):333-342.(PubMed Central)
- Prior M, et al. The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer’s disease mice. Alzheimers Res Ther. 2013;5(3):25.(PubMed)
- Jeanneteau F, Arango-Lievano M. A Critical Role of Mitochondria in BDNF-Associated Synaptic Plasticity. Front Cell Neurosci. 2018;12:1-8.(PubMed Central)
